A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.

By M. Morice, Patrick W. Serruys, J. Sousa, J. Fajadet, E.Ban Hayashi, M. Perin, A. Colombo, G. Schuler, P. Barragan, G. Guagliumi and 2 more. New England Journal of Medicine, 2002

2,829 citations recorded by the source corpus.

Subfields: Immunology, Surgery

View Paper: https://www.semanticscholar.org/paper/cfc0dc9eea701ae1c8433aace967b204041c9622

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Z. Bloomgarden

In Surgery

1. A. Kappas
2. Nader G. Abraham
3. J. Blenis
4. Z. Bloomgarden

Citations in the corpus

• Pharmacological and Clinical Aspects of Heme Oxygenase (2008, positive): “Rapamycin, a macrolide antibiotic, blocks cell cycle progression at the G1 phase and rapamycin-coated coronary stents have been shown to reduce coronary restenosis (Morice et al., 2002).”
• Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies (2002, neutral): “P [62]”
• Inflammation and insulin resistance. (2003, background): “Sirolimus binds to an intracellular site and when used to coat a stent decreases restenosis from 26% to nil (48).”